| 2026-02-23 |
详情>>
内部人交易：
Nayak Sanjay等共交易4笔
|
| 2026-02-05 |
详情>>
股本变动：
变动后总股本21769.18万股
|
| 2026-02-05 |
详情>>
业绩披露：
2025年年报每股收益-1.42美元,归母净利润-2.66亿美元,同比去年增长-37.43%
|
| 2025-11-04 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.15美元,归母净利润-2.01亿美元,同比去年增长-38.7%
|
| 2025-11-04 |
财报披露：
美东时间 2025-11-04 盘前发布财报
|
| 2025-08-05 |
详情>>
业绩披露：
2025年中报每股收益-0.77美元,归母净利润-1.32亿美元,同比去年增长-21.4%
|
| 2025-05-05 |
详情>>
业绩披露：
2025年一季报每股收益-0.38美元,归母净利润-6405.3万美元,同比去年增长1.23%
|
| 2025-04-29 |
股东大会：
将于2025-06-11召开股东大会
会议内容 ▼▲
- 1.To elect three class II directors of our board of directors to serve until the 2028 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified;
2.To hold an advisory vote on named executive officer compensation;
3.To approve an amendment to the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, to increase the number of shares of common stock issuable thereunder by 8,750,000 shares;
4.To approve an amendment and restatement of the Ocular Therapeutix, Inc. 2014 Employee Stock Purchase Plan to increase the number of shares of common stock issuable thereunder by 2,000,000 shares and to remove the annual “evergreen” provision;
5.To approve an amendment of our Restated Certificate of Incorporation, as amended, to provide for officer exculpation;
6.To ratify the appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix’s independent registered public accounting firm for the fiscal year ending December 31, 2025;
7.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2025-03-03 |
详情>>
业绩披露：
2024年年报每股收益-1.22美元,归母净利润-1.94亿美元,同比去年增长-139.68%
|
| 2025-03-03 |
详情>>
业绩披露：
2022年年报每股收益-0.92美元,归母净利润-7103.8万美元,同比去年增长-984.05%
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.94美元,归母净利润-1.45亿美元,同比去年增长-181.7%
|
| 2024-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.66美元,归母净利润-5151.6万美元,同比去年增长7.17%
|
| 2024-08-07 |
详情>>
业绩披露：
2024年中报每股收益-0.73美元,归母净利润-1.09亿美元,同比去年增长-112.99%
|
| 2024-05-07 |
详情>>
业绩披露：
2024年一季报每股收益-0.49美元,归母净利润-6484.8万美元,同比去年增长-113.89%
|
| 2024-04-29 |
股东大会：
将于2024-06-12召开股东大会
会议内容 ▼▲
- 1.To elect two class I directors of our board of directors to serve until the 2027 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified;
2.To hold an advisory vote on named executive officer compensation;
3.To approve an amendment to the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, to increase the number of shares of common stock issuable thereunder by 7,000,000 shares;
4.To approve an amendment to our Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock from 200,000,000 shares to 400,000,000 shares;
5.To ratify the appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix’s independent registered public accounting firm for the fiscal year ending December 31, 2024;
6.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-03-11 |
详情>>
业绩披露：
2023年年报每股收益-1.01美元,归母净利润-8073.6万美元,同比去年增长-13.65%
|
| 2023-05-01 |
股东大会：
将于2023-06-14召开股东大会
会议内容 ▼▲
- 1.To elect two class III directors of our board of directors to serve until the 2026 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified;
2.To hold an advisory vote on named executive officer compensation;
3.To approve an amendment to the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, to increase the number of shares of common stock issuable thereunder by 3,900,000 shares;
4.To ratify the selection of PricewaterhouseCoopers LLP as Ocular Therapeutix’s independent registered public accounting firm for the fiscal year ending December 31, 2023;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2022-09-30 |
复牌提示：
2022-09-29 15:47:53 停牌，复牌日期 2022-09-29 16:00:01
|
| 2022-05-02 |
股东大会：
将于2022-06-16召开股东大会
会议内容 ▼▲
- 1.To elect three class II directors of our board of directors to serve until the 2025 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified;
2.To hold an advisory vote on named executive officer compensation;
3.To approve an amendment to the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan to increase the number of shares of common stock issuable thereunder by 3,600,000 shares;
4.To ratify the selection of PricewaterhouseCoopers LLP as Ocular Therapeutix’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
5.To transact such other business as may properly come before the 2022 Annual Meeting of Stockholders or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-29 |
股东大会：
将于2021-06-18召开股东大会
会议内容 ▼▲
- 1.To elect two class I directors of our board of directors to serve until the 2024 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified;
2.To hold an advisory vote on named executive officer compensation;
3.To approve the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan;
4.To approve an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from 100,000,000 to 200,000,000;
5.To ratify the selection of PricewaterhouseCoopers LLP as Ocular Therapeutix’s independent registered public accounting firm for the fiscal year ending December 31, 2021;
6.To transact such other business as may properly come before the 2021 Annual Meeting or any adjournment or postponement thereof.
|
| 2020-04-29 |
股东大会：
将于2020-06-25召开股东大会
会议内容 ▼▲
- 1.To elect two class III directors of our board of directors to serve until the 2022 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified;
2.To hold an advisory vote on named executive officer compensation;
3.To hold an advisory vote on the frequency of future advisory votes on named executive officer compensation;
4.To ratify the selection of PricewaterhouseCoopers LLP as Ocular Therapeutix’s independent registered public accounting firm for the fiscal year ending December 31, 2020;
5.To transact such other business as may properly come before the 2020 Annual Meeting or any adjournment or postponement thereof.
|
| 2019-04-25 |
股东大会：
将于2019-06-11召开股东大会
会议内容 ▼▲
- 1.To elect three class II directors of our board of directors to serve until the 2022 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified;
2.To ratify the selection of PricewaterhouseCoopers LLP as Ocular Therapeutix’s independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.To transact such other business as may properly come before the 2019 Annual Meeting or any adjournment or postponement thereof.
|
| 2018-04-23 |
股东大会：
将于2018-06-14召开股东大会
会议内容 ▼▲
- 1.To elect three class I directors of our board of directors to serve until the 2021 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified.
2.To ratify the selection of PricewaterhouseCoopers LLP as Ocular Therapeutix’s independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.To transact such other business as may properly come before the 2018 Annual Meeting or any adjournment or postponement thereof.
|
| 2017-04-20 |
股东大会：
将于2017-06-01召开股东大会
会议内容 ▼▲
- 1. To elect three class III directors of our board of directors to serve until the 2020 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified;
2. To ratify the selection of PricewaterhouseCoopers LLP as Ocular Therapeutix’s independent registered public accounting firm for the fiscal year ending December 31, 2017;
3. To transact such other business as may properly come before the 2017 Annual Meeting or any adjournment or postponement thereof.
|
| 2016-04-22 |
股东大会：
将于2016-06-02召开股东大会
会议内容 ▼▲
- 1. To elect two class II directors of our board of directors to serve until the 2019 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified;
2. To ratify the selection of PricewaterhouseCoopers LLP as Ocular Therapeutix’s independent registered public accounting firm for the fiscal year ending December 31, 2016;
3. To transact such other business as may properly come before the 2016 Annual Meeting or any adjournment or postponement thereof.
|